Want to join the conversation?
Biopharmaceutical company $ALXN said while the REGAIN study missed its primary endpoint, patients achieved clinically meaningful improvements in MG-ADL and QMG measures when treated with eculizumab compared with placebo. The REGAIN study is a Phase 3 registration trial of eculizumab in patients with refractory generalized myasthenia gravis.
$TWTR comes out with another round of updates that directly aims at silencing abusers.
$WTW Great marketing execution and overwhelming response to the development strategy is seeing the stock boom. Biggest intraday gain ( 30%) since Nov. 2015. Hats off to Oprah Winfrey !!
$HSY is planning to cut its global workforce by 15%.
$ACN spreading its arms!! Now into pipeline network and emergency management services, thanks to the latest Davies Consulting buy.